Stevanato Group S.p.A. (STVN) saw its stock price soar 15.68% during intraday trading on Wednesday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.

The pharmaceutical services provider reported quarterly adjusted earnings of €0.18 per share, surpassing analyst estimates of €0.17. Revenue for the quarter reached €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by exceptional growth in high-value solutions, with revenue from this segment jumping 31% to a record €171.4 million, representing 49% of total Q4 revenue.

Additionally, Stevanato Group provided optimistic guidance for fiscal year 2026, forecasting revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted earnings per share between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.